Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
CNS Drugs|January 22, 2010
Therapeutic options for treatment-resistant depressionRichard C Shelton, Olawale Osuntokun, Alexandra N Heinloth, et al.Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|May 8, 2014
Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorderElizabeth Brunner, Mauricio Tohen, Olawale Osuntokun, et al.BMC Psychiatry|May 19, 2011
Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychoticsHong Liu-Seifert, Haya Ascher-Svanum, Olawale Osuntokun, et al.Journal of Child and Adolescent Psychopharmacology|March 1, 2012
Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapineLudmila A Kryzhanovskaya, Wen Xu, Brian A Millen, et al.The Journal of Clinical Psychiatry|March 28, 2009
A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophreniaJohn M Kane, Olawale Osuntokun, Ludmila A Kryzhanovskaya, et al.Journal of Psychopharmacology (Oxford, England)|May 26, 2010
Metabolic parameters in patients treated with olanzapine or other atypical antipsychoticsOlawale Osuntokun, Brian Millen, Wen I Xu, et al.The Journal of Clinical Psychiatry|March 6, 2007
A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorderMichael E Thase, Sara A Corya, Olawale Osuntokun, et al.The Journal of Clinical Psychiatry|March 17, 2009
An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depressionMadhukar H Trivedi, Michael E Thase, Olawale Osuntokun, et al.The British Journal of Dermatology|July 6, 2022
Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)Andrew Blauvelt, Alexa B Kimball, Matthias Augustin, et al.The Lancet. Rheumatology|January 22, 2024
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind studyKim Papp, Richard B Warren, Lawrence Green, et al.Pageof 2